UNCY (Unicycive Therapeutics) Interest Expense : $-0.07 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Unicycive Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Unicycive Therapeutics's interest expense for the three months ended in Dec. 2024 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.07 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Unicycive Therapeutics's Operating Income for the three months ended in Dec. 2024 was $ -9.26 Mil. Unicycive Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $ -0.02 Mil. Unicycive Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Unicycive Therapeutics Interest Expense Historical Data

The historical data trend for Unicycive Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unicycive Therapeutics Interest Expense Chart

Unicycive Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.24

-0.63

-0.01

-0.08

-0.07

Unicycive Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-0.02	-0.02	-0.02	-0.02	-0.02

Unicycive Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07 Mil.

Unicycive Therapeutics (NAS:UNCY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Unicycive Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $-0.02 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-9.26 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.12 Mil.

Unicycive Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Unicycive Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Unicycive Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unicycive Therapeutics Inc (NAS:UNCY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022

Website

https://www.unicycive.com

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Executives

Sandeep Laumas	director	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
John L Ryan	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Sara Kenkare-mitra	director	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gaurav Aggarwal	director	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Douglas Jermasek	other: EVP of Corporate Strategy	4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022
Brigitte Schiller	director	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
John Townsend	officer: Chief Financial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Pramod Gupta	officer: EVP, Pharmaceuticals and BD	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
Shalabh K. Gupta	director, officer: CEO	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022